Controller Forums

Our Controller Forums

Controllers, please join us in our forum for members of the HIV Controller community — a place to share your story, talk, and make new friends! Get linked to clinical research studies and follow the adventures of our members who travel to participate in them!

To join, click "Register" at the bottom of this page and follow the instructions. You will need to have the "passphrase" from your invitation. If you are a controller and haven't received an invitation,  send us an email using the "Contact Us" link above.

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals Print E-mail
  
Thursday, 19 March 2009 07:05
Antibodies to conserved epitopes on the human immunodeficiency virus (HIV) surface protein gp140 can protect against infection in non-human primates, and some infected individuals show high titres of broadly neutralizing immunoglobulin (Ig)G antibodies in their serum. However, little is known about the specificity and activity of these antibodies1, 2, 3. To characterize the memory antibody responses to HIV, we cloned 502 antibodies from HIV envelope-binding memory B cells from six HIV-infected patients with broadly neutralizing antibodies and low to intermediate viral loads. We show that in these patients, the B-cell memory response to gp140 is composed of up to 50 independent clones expressing high affinity neutralizing antibodies to the gp120 variable loops, the CD4-binding site, the co-receptor-binding site, and to a new neutralizing epitope that is in the same region of gp120 as the CD4-binding site. Thus, the IgG memory B-cell compartment in the selected group of patients with broad serum neutralizing activity to HIV is comprised of multiple clonal responses with neutralizing activity directed against several epitopes on gp120.
Correspondence to: This e-mail address is being protected from spambots. You need JavaScript enabled to view it 1,5 Correspondence and requests for materials should be addressed to M.C.N.

Link: http://www.nature.com/nature/journal/vaop/ncurrent/abs/nature07930.html

Johannes F. Scheid1,6, Hugo Mouquet1, Niklas Feldhahn1, Michael S. Seaman7, Klara Velinzon1, John Pietzsch1,8, Rene G. Ott2, Robert M. Anthony2, Henry Zebroski3, Arlene Hurley4, Adhuna Phogat9, Bimal Chakrabarti9, Yuxing Li9, Mark Connors10, Florencia Pereyra11, Bruce D. Walker11, Hedda Wardemann12, David Ho13, Richard T. Wyatt9, John R. Mascola9, Jeffrey V. Ravetch2 & Michel C. Nussenzweig1,5

  1. Laboratory of Molecular Immunology,
  2. Laboratory of Molecular Genetics and Immunology,
  3. Proteomics Resource Center,
  4. Rockefeller University Hospital, and,
  5. Howard Hughes Medical Institute, The Rockefeller University, New York, New York 10065, USA
  6. Charite Universitaetsmedizin, D-10117 Berlin, Germany
  7. Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
  8. Institute of Chemistry and Biochemistry, Freie Universität Berlin, D-14195 Berlin, Germany
  9. Vaccine Research Center, and,
  10. Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health Bethesda, Maryland 20892, USA
  11. Partners AIDS Research Center, Mass General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA
  12. Max Planck Institute for Infection Biology, D-10117 Berlin, Germany
  13. Aaron Diamond Aids Research Center; New York, New York 10065, USA
Del.icio.us     Digg This!     Facebook     Google     Reddit     Stumble It!
Last Updated ( Thursday, 19 March 2009 07:41 )